Phase II study of amrubicin plus erlotinib in previously treated, advanced non-small cell lung cancer with wild-type epidermal growth factor receptor (TORG1320) [0.03%]
阿美乐联合厄洛替尼治疗野生型表皮生长因子受体晚期非小细胞肺癌患者的II期临床研究(TORG1320)
Sakiko Otani,Jiichiro Sasaki,Yoshiro Nakahara et al.
Sakiko Otani et al.
Background Amrubicin (AMR) is a completely synthetic 9-aminoanthracycline and clinically active against non-small cell lung cancer (NSCLC). We conducted a phase I study of AMR and erlotinib (ERL) combination therapy in previously treated pa...
Autophagy modulating agents as chemosensitizers for cisplatin therapy in cancer [0.03%]
自噬调节剂作为顺铂癌症治疗的增敏剂
Bartosz Mateusz Gąsiorkiewicz,Paulina Koczurkiewicz-Adamczyk,Kamil Piska et al.
Bartosz Mateusz Gąsiorkiewicz et al.
Although cisplatin is one of the most common antineoplastic drug, its successful utilisation in cancer treatment is limited by the drug resistance. Multiple attempts have been made to find potential cisplatin chemosensitisers which would ov...
Nab-paclitaxel-based regimens with docetaxel-based regimens as neoadjuvant treatment for early breast cancer [0.03%]
以多西他赛为基础的新辅助治疗与白蛋白结合型紫杉醇为基础的新辅助治疗早期乳腺癌的对比研究
Yimeng Chen,Baoshi Bao,Yao Lv et al.
Yimeng Chen et al.
Background Nanoparticle albumin-bound paclitaxel (nab-PTX) and docetaxel (DOC) both demonstrated favorable efficacy as neoadjuvant therapy in breast cancer. We retrospectively evaluated the efficacy and safety of nab-PTX-based chemotherapy ...
Notoginsenoside R1 counteracts mesenchymal stem cell-evoked oncogenesis and doxorubicin resistance in osteosarcoma cells by blocking IL-6 secretion-induced JAK2/STAT3 signaling [0.03%]
诺高辛苷R1通过阻断IL-6介导的JAK2 / STAT3信号传导对抗骨肉瘤细胞中的间充质干细胞诱导的促癌和多柔比星抗性
Minan Lu,Kegong Xie,Xianzhe Lu et al.
Minan Lu et al.
Tumor microenvironment is a critical participant in the initiation, progression and drug resistance of carcinomas, including osteosarcoma. Notoginsenoside R1 (NGR1) is a proverbial active ingredient of the traditional Chinese medicine Panax...
Comment on: an orally antitumor chalcone hybrid inhibited HepG2 cells growth and migration as the tubulin binding agent [0.03%]
关于抗肿瘤口服查尔康素抑制肝癌细胞增殖和迁移作为结合微管的活性分子的评论
Xinxiao Li,Renba Liang
Xinxiao Li
Recently we read a paper in Investigational New Drugs "An orally antitumor chalcone hybrid inhibited HepG2 cells growth and migration as the tubulin binding agent". Chalcone hybrid 9, a novel chalcone derivative, may be a promising agent fo...
Absorption of the orally active multikinase inhibitor axitinib as a therapeutic index to guide dose titration in metastatic renal cell carcinoma [0.03%]
口服多激酶抑制剂阿西替尼的吸收作为转移性肾细胞癌剂量递增的治疗指数
Masahide Fukudo,Gaku Tamaki,Makoto Azumi et al.
Masahide Fukudo et al.
Purpose Axitinib is an orally active multikinase inhibitor currently used to treat patients with metastatic renal cell carcinoma (RCC). This study examined the pharmacokinetics of axitinib and the relationship between peak drug concentratio...
A retrospective comparative study of S-IROX and modified FOLFIRINOX for patients with advanced pancreatic cancer refractory to gemcitabine plus nab-paclitaxel [0.03%]
S-IROX 和修改版FOLFIRINOX对吉西他滨联合 Nab-紫杉醇耐药的晚期胰腺癌患者的回顾性对比研究
Kei Saito,Yousuke Nakai,Naminatsu Takahara et al.
Kei Saito et al.
Purpose: The aim of this study was to evaluate the efficacy and tolerability of S-IROX and modified FOLFIRINOX (mFFX) after gemcitabine plus nab-paclitaxel for advanced pancreatic cancer (PC) in the real world setting. ...
Phase I study assessing the mass balance, pharmacokinetics, and excretion of [14C]-pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors [0.03%]
评估NEDD8激活酶抑制剂[14C] - pevonedistat的质量平衡、药代动力学和排泄的一期研究在晚期实体瘤患者中进行
Xiaofei Zhou,Farhad Sedarati,Douglas V Faller et al.
Xiaofei Zhou et al.
Pevonedistat (TAK-924/MLN4924) is an investigational small-molecule inhibitor of the NEDD8-activating enzyme that has demonstrated preclinical and clinical activity across solid tumors and hematological malignancies. Here we report the resu...
Recombinant human endostatin plus paclitaxel/nedaplatin for recurrent or metastatic advanced esophageal squamous cell carcinoma: a prospective, single-arm, open-label, phase II study [0.03%]
重组人内皮抑素联合紫杉醇/奈达铂治疗局部复发或远处转移的晚期食管鳞癌的临床研究——一项单臂开放标签的二期试验
Zhi-Qiang Wang,De-Shen Wang,Feng-Hua Wang et al.
Zhi-Qiang Wang et al.
Background The prognosis of esophageal squamous cell carcinoma (ESCC) are still poor. Nedaplatin/paclitaxel regimen has shown activity with lower toxicity in metastatic ESCC. Recombinant human endostatin (Rh-endostatin), an inhibitor of ang...
Recombinant human lactoferrin carrying humanized glycosylation exhibits antileukemia selective cytotoxicity, microfilament disruption, cell cycle arrest, and apoptosis activities [0.03%]
携带人源化糖基化的重组人乳铁蛋白表现出抗白血病的选择性细胞毒性,微丝破坏,细胞周期阻滞和凋亡活性
Sayuri Nakamura-Bencomo,Denisse A Gutierrez,Elisa Robles-Escajeda et al.
Sayuri Nakamura-Bencomo et al.
Lactoferrin has gained extensive attention due to its ample biological properties. In this study, recombinant human lactoferrin carrying humanized glycosylation (rhLf-h-glycan) expressed in the yeast Pichia pastoris SuperMan5, which is gene...